{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:40:43Z","timestamp":1790257243011,"version":"4.1.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Accurate assessment of GFR is key in patients with cancer to guide drug eligibility, adjust dosing of systemic therapy, and minimize the risks of undertreatment and systemic toxicity. Several aspects of GFR evaluation in patients with cancer have been unclear, such as the choice of the GFR estimating equation and the overall lack of data on the reliability of new filtration markers, such as cystatin C. This uncertainty has led to concerns that inaccurate GFR estimation may have a large effect on clinical practice and research. Recent data have brought important developments to the field. The new and timely Kidney Disease Improving Global Outcomes 2024 Clinical Practice Guideline for the Evaluation and Management of CKD raised important considerations and provided guidance on key aspects of GFR evaluation in patients with cancer. The guidelines cover valid estimating equations, incorporation of cystatin C in GFR estimation, drawbacks of using race in GFR estimation, and acknowledge that non-GFR determinants of filtration markers may be prominent in patients with cancer, reducing the accuracy of GFR estimating equations, prompting greater utilization of GFR measurement. The aim of this review is to summarize advances in GFR evaluation in patients with cancer considering the new Kidney Disease Improving Global Outcomes guidelines and other recent data.<\/jats:p>","DOI":"10.34067\/kid.0000000736","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:00:55Z","timestamp":1740398455000},"page":"861-870","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Update on the Assessment of GFR in Patients with Cancer"],"prefix":"10.34067","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8211-018X","authenticated-orcid":false,"given":"Ver\u00f4nica T.","family":"Costa e Silva","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Nefrologia, Faculdade de Medicina, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"Laborat\u00f3rio de Investiga\u00e7\u00e3o M\u00e9dica (LIM) 16, Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0966-5263","authenticated-orcid":false,"given":"Fei","family":"Xiong","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0998-8812","authenticated-orcid":false,"given":"Lea","family":"Mantz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Sise","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4537","authenticated-orcid":false,"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-5046","authenticated-orcid":false,"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"issue":"6","key":"B1-20250530","doi-asserted-by":"crossref","first-page":"151340","DOI":"10.1016\/j.semnephrol.2023.151340","article-title":"Glomerular filtration rate measurement and chemotherapy dosing","volume":"42","author":"Rosner","year":"2022","journal-title":"Semin Nephrol."},{"issue":"23","key":"B2-20250530","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.2018.7260","article-title":"Representation of patients with chronic kidney disease in trials of cancer therapy","volume":"319","author":"Kitchlu","year":"2018","journal-title":"JAMA."},{"issue":"24","key":"B3-20250530","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2017.72.7578","article-title":"New model for estimating glomerular filtration rate in patients with cancer","volume":"35","author":"Janowitz","year":"2017","journal-title":"J Clin Oncol."},{"issue":"3","key":"B4-20250530","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.kint.2021.12.010","article-title":"A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors","volume":"101","author":"Costa E Silva","year":"2022","journal-title":"Kidney Int."},{"issue":"8","key":"B5-20250530","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","article-title":"Assessment of GFR in patients with cancer: a statement from the American Society of Onco-Nephrology","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B6-20250530","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int."},{"issue":"1","key":"B7-20250530","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med."},{"issue":"1","key":"B8-20250530","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41581-019-0191-y","article-title":"Measured and estimated glomerular filtration rate: current status and future directions","volume":"16","author":"Levey","year":"2020","journal-title":"Nat Rev Nephrol."},{"issue":"11","key":"B9-20250530","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/ndt\/gfae120","article-title":"Combined creatinine\/cystatin C equations for estimation of GFR in patients with cancer: the future is now","volume":"39","author":"Vanhoutte","year":"2024","journal-title":"Nephrol Dial Transplant."},{"issue":"8","key":"B10-20250530","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2215\/CJN.0000000000000509","article-title":"Assessment of GFR in patients with cancer Part 2: anticancer therapies-perspectives from the American Society of Onco-Nephrology (ASON)","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"B11-20250530","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/jpen.2415","article-title":"Prevalence of sarcopenia in patients with solid tumors: a meta-analysis based on 81,814 patients","volume":"46","author":"Surov","year":"2022","journal-title":"JPEN J Parenter Enteral Nutr."},{"issue":"4","key":"B12-20250530","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11764-012-0234-x","article-title":"Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study","volume":"6","author":"Villasenor","year":"2012","journal-title":"J Cancer Surviv."},{"issue":"3","key":"B13-20250530","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3109\/0284186X.2014.953259","article-title":"Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer","volume":"54","author":"Stene","year":"2015","journal-title":"Acta Oncol."},{"issue":"1","key":"B14-20250530","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/annonc\/mdu501","article-title":"Nutritional assessment in overweight and obese patients with metastatic cancer: does it make sense?","volume":"26","author":"Gioulbasanis","year":"2015","journal-title":"Ann Oncol."},{"issue":"5","key":"B15-20250530","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1634\/theoncologist.2009-0283","article-title":"The diversity of nutritional status in cancer: new insights","volume":"15","author":"Ramos Chaves","year":"2010","journal-title":"Oncologist."},{"issue":"5","key":"B16-20250530","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/jcsm.12756","article-title":"Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis","volume":"12","author":"Martin","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"1","key":"B17-20250530","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40620-022-01409-7","article-title":"Association of dietary proteins with serum creatinine and estimated glomerular filtration rate in a general population sample: the CHRIS study","volume":"36","author":"Vukovic","year":"2023","journal-title":"J Nephrol."},{"issue":"7","key":"B18-20250530","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol."},{"issue":"6","key":"B19-20250530","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int."},{"key":"B20-20250530","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.lfs.2018.04.013","article-title":"On the role of cystatin C in cancer progression","volume":"202","author":"Leto","year":"2018","journal-title":"Life Sci."},{"issue":"3","key":"B21-20250530","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1053\/j.ajkd.2017.03.021","article-title":"Non-GFR determinants of low-molecular-weight serum protein filtration markers in the elderly: AGES-kidney and MESA-kidney","volume":"70","author":"Foster","year":"2017","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B22-20250530","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ndt\/gfad219","article-title":"Accuracy of GFR estimating equations based on creatinine, cystatin C or both in routine care","volume":"39","author":"Fu","year":"2024","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B23-20250530","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00330-019-06573-2","article-title":"Imaging of sarcopenia: old evidence and new insights","volume":"30","author":"Albano","year":"2020","journal-title":"Eur Radiol."},{"issue":"1","key":"B24-20250530","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/RLI.0000000000000799","article-title":"Whole-body composition profiling using a deep learning algorithm: influence of different acquisition parameters on algorithm performance and robustness","volume":"57","author":"Huber","year":"2022","journal-title":"Invest Radiol."},{"issue":"5","key":"B25-20250530","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MCO.0000000000000395","article-title":"A requiem for BMI in the clinical setting","volume":"20","author":"Gonzalez","year":"2017","journal-title":"Curr Opin Clin Nutr Metab Care."},{"issue":"2","key":"B26-20250530","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jpainsymman.2011.09.010","article-title":"Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study","volume":"44","author":"Dalal","year":"2012","journal-title":"J Pain Symptom Manage."},{"issue":"5","key":"B27-20250530","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/bjs.10075","article-title":"Influence of body composition profile on outcomes following colorectal cancer surgery","volume":"103","author":"Malietzis","year":"2016","journal-title":"Br J Surg."},{"issue":"3","key":"B28-20250530","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/jcsm.13469","article-title":"Sarcopenia, adiposity and large discordance between cystatin C and creatinine-based estimated glomerular filtration rate in patients with cancer","volume":"15","author":"Hanna","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"7","key":"B29-20250530","doi-asserted-by":"crossref","first-page":"e2321715","DOI":"10.1001\/jamanetworkopen.2023.21715","article-title":"Medication-related adverse events and discordancies in cystatin C-based vs serum creatinine-based estimated glomerular filtration rate in patients with cancer","volume":"6","author":"Hanna","year":"2023","journal-title":"JAMA Netw Open."},{"issue":"2","key":"B30-20250530","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/RLI.0000000000001104","article-title":"Subcutaneous and visceral adipose tissue reference values from the framingham heart study thoracic and abdominal CT","volume":"60","author":"Marquardt","year":"2025","journal-title":"Invest Radiol."},{"issue":"3","key":"B31-20250530","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/RLI.0000000000001012","article-title":"Muscle reference values from thoracic and abdominal CT for sarcopenia assessment: the framingham heart study","volume":"59","author":"Tonnesen","year":"2024","journal-title":"Invest Radiol."},{"issue":"5","key":"B32-20250530","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1007\/s00330-021-08313-x","article-title":"End-to-end automated body composition analyses with integrated quality control for opportunistic assessment of sarcopenia in CT","volume":"32","author":"Nowak","year":"2022","journal-title":"Eur Radiol."},{"issue":"2","key":"B33-20250530","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1148\/radiol.2020201640","article-title":"Population-scale CT-based body composition analysis of a large outpatient population using deep learning to derive age-sex-and race-specific reference curves","volume":"298","author":"Magudia","year":"2021","journal-title":"Radiology."},{"issue":"5","key":"B34-20250530","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMms2029562","article-title":"Race and genetic ancestry in medicine - a time for reckoning with racism","volume":"384","author":"Borrell","year":"2021","journal-title":"N Engl J Med."},{"issue":"19","key":"B35-20250530","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med."},{"issue":"9","key":"B36-20250530","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S1470-2045(21)00377-6","article-title":"Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants","volume":"22","author":"Casal","year":"2021","journal-title":"Lancet Oncol."},{"key":"B37-20250530","doi-asserted-by":"crossref","first-page":"216679","DOI":"10.1016\/j.canlet.2024.216679","article-title":"Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients","volume":"586","author":"Butrovich","year":"2024","journal-title":"Cancer Lett."},{"issue":"2","key":"B38-20250530","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1053\/j.ajkd.2023.01.445","article-title":"A prospective cross-sectional study on the performance of the 2021 CKD-EPI equations without race in a multiracial population of adults with solid tumors in Brazil","volume":"82","author":"Costa E Silva","year":"2023","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"B39-20250530","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1053\/j.ajkd.2024.01.532","article-title":"Glomerular filtration rate estimation using \u03b22-microglobulin and \u03b2-trace protein in adults with solid tumors: a prospective cross-sectional study","volume":"84","author":"Costa E Silva","year":"2024","journal-title":"Am J Kidney Dis."},{"issue":"8","key":"B40-20250530","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/ckj\/sfab042","article-title":"Assessment of kidney function: clinical indications for measured GFR","volume":"14","author":"Ebert","year":"2021","journal-title":"Clin Kidney J."},{"issue":"4","key":"B41-20250530","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.kint.2024.06.029","article-title":"Iohexol plasma clearance measurement protocol standardization for adults: a consensus paper of the European Kidney Function Consortium","volume":"106","author":"Ebert","year":"2024","journal-title":"Kidney Int."},{"issue":"5","key":"B42-20250530","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ckj\/sfw070","article-title":"Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: how to measure glomerular filtration rate with iohexol?","volume":"9","author":"Delanaye","year":"2016","journal-title":"Clin Kidney J."},{"issue":"2","key":"B44-20250530","doi-asserted-by":"crossref","first-page":"141","DOI":"10.34067\/KID.0000952019","article-title":"GFR measurement and chemotherapy dosing in patients with kidney disease and cancer","volume":"1","author":"McMahon","year":"2020","journal-title":"Kidney360."},{"issue":"4","key":"B45-20250530","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.kint.2024.06.012","article-title":"Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102)","volume":"106","author":"Dorshow","year":"2024","journal-title":"Kidney Int."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:03:00Z","timestamp":1786478580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000736","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}